FAFSA deadline approaching, students urged to seek aid now
LAS VEGAS (KLAS) – An important deadline is quickly approaching for students heading to college this fall.
The FAFSA, or Free Application for Federal Student Aid, must be submitted by the end of the month. The application is the first step to accessing billions of dollars in financial aid.
'FAFSA unlocks federal grants, loans, and work-study as well as many state and college programs' aid on a first-come, first-served basis,' Shaan Patel, Founder and CEO of PrepExpert.com, an online college prep service, said.
The entire application can be completed online.
'Make sure you have all your necessary documents… so you get the maximum financial aid possible for college this fall,' Patel said.
Dr. Rhea Watson, also known as The Scholarship Doctor and CEO of Scholarship Solutions, warns that skipping the FAFSA could cost you thousands of dollars. She emphasizes that it's a mistake to assume you won't qualify for financial aid.
'If you don't have a FAFSA application on file, it is nearly impossible, very difficult for your scholarship applications and even those financial aid packages you want to receive from a college,' Watson said.
Roughly $3 billion in aid goes unclaimed every year, Watson said.
'Don't leave money on the table… it just goes and recycles through the government versus going to students who can use it to go to school and go without debt,' Watson said.
The FAFSA only takes a few hours to complete if one is prepared. Once submitted, one can expect the financial aid award letter within 2 to 3 weeks. However, keep in mind that state and school-specific aid can run out quickly, so it's best to apply as early as possible.
Documents needed for filling out the FAFSA include:
Social Security number
Parents' Social Security numbers (if you are a dependent student)
Tax returns
Records of child support received
Current balances of cash, savings, and checking accounts
Social Security card, driver's license, and/or alien registration card (if not a US citizen)
Federal income tax returns, W-2s, and other records of money earned
For more information on what students need to know before they fill out the FAFSA form, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. A lab scientist peering into a microscope focused on gene editing technology. All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks. Positive safety results were maintained across all treatment dosages. The current Phase 3 HAELO trial has a majority of U.S. enrollment and has completed screening ahead of schedule. Intellia Therapeutics, Inc. (NASDAQ:NTLA) plans to launch in 2027 after submitting a BLA in 2026. Lonvo-z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications. Administered intravenously at doses ranging from 25 to 75 mg, the therapy demonstrated dose-dependent kallikrein protein decrease and long-term efficacy, with no major treatment-related side effects recorded. While we acknowledge the potential of NTLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
20 minutes ago
- Yahoo
Lilly To Acquire Verve For One-Time Cardiovascular Treatments
Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc. (NASDAQ:VERV)'s 30-day average share price as of June 16, 2025. Single-dose gene-editing therapies for atherosclerotic cardiovascular disease are being developed by Verve Therapeutics, Inc. (NASDAQ:VERV), including their flagship program VERVE-102, which targets PCSK9. The medication, which is currently in Phase 1b and has been granted FDA Fast Track designation, has the potential to transform care for patients suffering from heterozygous familial hypercholesterolemia and early coronary artery disease. According to Lilly, Verve Therapeutics, Inc. (NASDAQ:VERV)'s platform strengthens its cardiometabolic pipeline. Sekar Kathiresan, CEO of Verve, stressed the company's goal of moving from chronic to one-time care. Insiders of the firm who own 17.8% of the company have decided to tender. While we acknowledge the potential of VERV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
10x Genomics Settles Patent Dispute With Bruker
10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms. A team of medical professionals in surgical scrubs analysing research data in a laboratory. As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments. Furthermore, Bruker will pay continuous royalties on sales of spatial biology products for the duration of the licensed patents. Global patent cross-licenses and the termination of all legal actions in the United States, Germany, and the European Unified Patent Court are part of the settlement. 10x Genomics, Inc. (NASDAQ:TXG), a leader in single-cell and spatial biology, pointed out the need for intellectual property protection to promote scientific innovation. CEO Serge Saxonov regarded the outcome as a validation of the company's vision and dedication to innovation. Eric Whitaker, Chief Legal Officer, noted the robustness of the firm's IP portfolio and its fundamental function in spatial biology. The settlement makes it possible to keep funding upcoming innovations. While we acknowledge the potential of TXG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
